---
id: antimicrobials_mdr-tb-treatment_039
category: antimicrobials
tags: [antimicrobials, MDR-TB, bedaquiline, linezolid, pretomanid, BPaL, fluoroquinolones]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Multidrug-Resistant Tuberculosis (MDR-TB) Treatment

**Q:** What defines MDR-TB, and what are the WHO-recommended treatment regimens as of 2024?

**A:**

**MDR-TB Definition:**
- Resistance to at least **rifampin AND isoniazid** (the 2 most potent first-line agents)
- Requires second-line drugs for treatment

**WHO 2024-Recommended Regimens:**

**1. BPaL Regimen (6 months, all-oral):**
- **B**edaquiline
- **P**retomanid
- **L**inezolid
- Duration: 6 months
- Success rate: 92%
- For MDR/RR-TB WITH fluoroquinolone resistance

**2. BPaLM Regimen (6 months, all-oral):**
- BPaL + **M**oxifloxacin
- Duration: 6 months
- For MDR/RR-TB WITHOUT fluoroquinolone resistance
- **Most commonly used** regimen globally (58 countries, 5,646 patients in 2023)

**3. Modified 9-Month Regimens (2024 Update):**
- Based on BEAT-TB and endTB trials
- **B**edaquiline + **D**elamanid + **L**inezolid + either:
  - Levofloxacin (Lfx), OR
  - Clofazimine (C), OR
  - Both
- For MDR/RR-TB without fluoroquinolone resistance

**Key Second-Line Agents:**

| **Drug** | **Class** | **Role** | **Major Toxicity** |
|----------|-----------|----------|-------------------|
| **Bedaquiline** | ATP synthase inhibitor | Backbone | QTc prolongation |
| **Linezolid** | Oxazolidinone | Backbone | Myelosuppression, peripheral neuropathy |
| **Fluoroquinolones** (levo, moxi) | DNA gyrase inhibitor | Backbone if susceptible | QTc, tendon rupture |
| **Pretomanid** | Nitroimidazole | Novel agent (BPaL) | Generally well-tolerated |
| **Delamanid** | Nitroimidazole | Alternative to pretomanid | QTc prolongation |
| **Amikacin, capreomycin** | Injectable aminoglycosides | Second-line (older regimens) | Nephrotoxicity, ototoxicity |
| **Clofazimine** | Riminophenazine | Additional agent | Skin discoloration |

**Mnemonic: "BPaL(M) for Modern MDR"**
- **B**edaquiline
- **P**retomanid
- **L**inezolid
- **(M)** oxifloxacin if FQ-susceptible

**Treatment Duration:**
- **BPaL/BPaLM:** 6 months (revolutionary - was 18-24 months historically)
- **Modified regimens:** 9 months
- **Old regimens:** 18-24 months

**Clinical Pearls:**
- **Linezolid toxicity** is dose- and duration-dependent:
  - Myelosuppression (monitor CBC weekly)
  - Peripheral neuropathy (can be irreversible)
  - Optic neuritis
- **QTc monitoring** required for bedaquiline, delamanid, fluoroquinolones
- **Drug susceptibility testing (DST)** essential to guide therapy
- Directly observed therapy (DOT) critical for MDR-TB

**Media:** None

**Sources:** [WHO 2024 Global TB Report - DR-TB treatment], [WHO 2022/2024 Consolidated Guidelines], [PMC 2025 - BPaL safety Italy], [PMC 2024 - Bedaquiline/linezolid meta-analysis], [Journal of Infection 2025 - BPaL outcomes], [UCSF Curry TB Center 2023 - BPaL Guidance]
